Entera Bio (ENTX) Other financing activities (2023 - 2026)
Entera Bio's (ENTX) quarterly Other financing activities came in at $130000.0 in Q1 2026, down 13.33% YoY from $150000.0 in Q1 2025, and down 15.58% on a QoQ basis from $154000.0 in Q4 2025.
Entera Bio (ENTX) Other financing activities (2023 - 2026) Analysis & Trends
Entera Bio (ENTX) has 4 years of Other financing activities data on file, last reported at $130000.0 in Q1 2026.
- Quarterly Other financing activities fell 13.33% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $488000.0 (down 39.68% YoY) and the FY2025 annual result came in at $508000.0, down 32.18% from the prior year.
- Other financing activities eased to $130000.0 in Q1 2026, from $154000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $6.6 million in Q4 2023 to a low of $13000.0 in Q3 2024.
- A 4-year average of $793800.0 and a median of $140000.0 in 2025 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities sank 98.62% — and 2025, when it soared 1284.62%.
- Tracing ENTX's Other financing activities over 4 years: stood at $6.6 million in 2023, then slumped by 98.62% to $91000.0 in 2024, then jumped by 69.23% to $154000.0 in 2025, then fell by 15.58% to $130000.0 in 2026.
- The last three Other financing activities figures came in at $130000.0 (Q1 2026), $154000.0 (Q4 2025), and $180000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 180,000.00 |
| Sep 30, 2025 | 180,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 555,000.00 |
| Jun 30, 2024 | 555,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 6.61 Mn |
| Dec 31, 2023 | 6.61 Mn |